Japanese delay for mogamulizumab in first line ATL
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin is facing a development delay for Poteligeo (mogamulizumab) in an additional indication in Japan following a decision by the firm temporarily to withdraw a regulatory filing.